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  The purpose of this investigation was to verify the non－specific cellular immune responses after
the cryoresection of the prostate． 1） Peripheral iymphocyte counts， 2） toxoplasma test， 3）
Mantoux test and 4） PHA－induced biastoid transformation of peripheral lymphocyte at pre一 and
post－operation were examined in 70 patients with benign prostatic hyperplasia and 34 patients with
prostatlc c4rcmoma．
  Peripheral lymphocyte counts of the patients with prostatic carcinoma was less than’that of the
patients with benign prostatic hyperp｝asia， especially at the second week after the cyroresection of the
prostate， significantlly （Pく0．05）．
  In other tests， there was no significant difference between benign prostatic hyperplasia and








































    和志田・ほか：前立腺cryoresection・細胞性免疫
Tablc l           滅菌試験管に移し，室温にて約3時間静置する．上層
                のleucocyte rich plasmaを採取し，800 rpmで5分
                間incubateした．5分間静置後，白血球血漿1，5 ml
                に，阪大微研製のmedium T・C・199を3mlと，
                Difco製のPHA－Mを約6滴加え，室温にて72時間
                培養した．1，000～1，500rpmで5分間incubateした
                後，沈渣をスパルヒン上に展開し，May－Giemsa染色
                後，顕微鏡下に幼若化したリンパ球数を算定した．リ
                ンパ球500個申に，いくつの幼若化リンパ球が存在す
                るかをもって，幼若化率を算出した．
＊BPH＝Benign Prostatic Hyperplasia
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